Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia

Background: microglia are considered a major target for modulating neuroinflammatory and neurodegenerative disease processes. upon activation,microglia secrete inflammatory mediators that contribute to the resolution or to further enhancement of damage in the central nervous system (cns). therefore,it is important to study the intracellular pathways that are involved in the expression of the inflammatory mediators. particularly,the role of the phosphatidylinositol 3-kinase (pi3k)/akt/mammalian target of rapamycin (mtor) and glycogen synthase kinase-3 (gsk-3) pathways in activated microglia is unclear. thus,in the present study we investigated the role of akt and its downstream pathways,gsk-3 and mtor,in lipopolysaccharide (lps)-activated primary rat microglia by pharmacological inhibition of these pathways in regard to the expression of cyclooxygenase (cox)-2 and microsomal prostaglandin e synthase-1 (mpges-1) and to the production of prostaglandin (pg) e 2and pgd 2.findings: we show that inhibition of akt by the akt inhibitor x enhanced the production of pge 2and pgd 2without affecting the expression of cox-2,mpges-1,mpges-2 and cytosolic prostaglandin e synthase (cpges). moreover,inhibition of gsk-3 reduced the expression of both cox-2 and mpges-1. in contrast,the mtor inhibitor rapamycin enhanced both cox-2 and mpges-1 immunoreactivity and the release of pge 2and pgd 2. interestingly,nvp-bez235,a dual pi3k/mtor inhibitor,enhanced cox-2 and reduced mpges-1 immunoreactivity,albeit pge 2and pgd 2levels were enhanced in lps-stimulated microglia. however,this compound also increased pge 2in non-stimulated microglia.conclusion: taken together,we demonstrate that blockade of mtor and/or pi3k/akt enhances prostanoid production and that pi3k/akt,gsk-3 and mtor differently regulate the expression of mpges-1 and cox-2 in activated primary microglia. therefore,these pathways are potential targets for the development of novel strategies to modulate neuroinflammation. © 2012 de oliveira et al; licensee biomed central ltd.